Abstract: Risperidone (RISP) is an antipsychotic agent and has
low water solubility and nontargeted delivery results in numerous
side effects. Hence, an attempt was made to develop SLNs hydrogel
for intranasal delivery of RISP to achieve maximum bioavailability
and reduction of side effects. RISP loaded SLNs composed of 1.65%
(w/v) lipid mass were produced by high shear homogenization (HSH)
coupled ultrasound (US) method using glycerylmonostearate (GMS)
or Imwitor 900K (solid lipid). The particles were loaded with 0.2%
(w/v) of the RISP & surface-tailored with a 2.02% (w/v) non-ionic
surfactant Tween® 80. Optimization was done using 32 factorial
design using Design Expert® software. The prepared SLNs
dispersion incorporated into Polycarbophil AA1 hydrogel (0.5%
w/v). The final gel formulation was evaluated for entrapment
efficiency, particle size, rheological properties, X ray diffraction, in
vitro diffusion, ex vivo permeation using sheep nasal mucosa and
histopathological studies for nasocilliary toxicity. The entrapment
efficiency of optimized SLNs was found to be 76 ± 2%,
polydispersity index